Skip NavigationMarketsBusinessInvestingTechPolitics & PolicyVideoWatchlistInvesting Club
PRO
LivestreamMenu
- UK pharmaceutical company AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb, according to a report by the Financial Times.
- The megadeal would be one of the largest in history, creating a combined company valued at $400 billion.
A smart acquisition strategy has made Bristol-Meyers, which has bought seven companies since October 2007, a big player in the cancer-treatment industry. Its purchase of Medarex in July added a key drug for metastic melanoma that’s in Phase III trials. The drug has possible multiple indications – industry jargon for its ability to treat more than one condition – for lung and prostate cancer.But BMY also sells Erbitux for colorectal, head and neck cancer, Ixempra for breast cancer, Taxol for brea
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb, in a deal that would value the joint company at roughly $400 billion, the Financial Times reported on Sunday.
It’s still unclear whether the deal will come together, but the companies have been discussing a merger over the last few months, sources told the FT.
The merger would be one of the largest in history.
AstraZeneca and Bristol Myers Squibb did not immediately respond to a CNBC request for comment.
Read the complete Financial Times story here.
This is a developing story. Please check back for updates.
WATCH: AstraZeneca CFO: Very confident we will hit $80 billion revenue target
watch nowVIDEO08:56AstraZeneca CFO: Very confident we will hit $80 billion revenue targetSquawk Box EuropeChoose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
About The Author
